Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
Hospital La Paz, Madrid, Comunidad De Madrid, Spain
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Royal Children's Hospital, Melbourne, Victoria, Australia
Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146), Los Angeles, California, United States
Tampa General Hospital (Site # 71150), Tampa, Florida, United States
NYU Langone Health (Site # 71177), New York, New York, United States
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
MD Anderson Cancer Center, Houston, Texas, United States
Grenoble University Hospital, Grenoble, Aura, France
Odense University Hospital, Odense, Denmark
Zealand University Hospital, Roskilde, Denmark
Lillebaelt Hospital, Vejle, Denmark
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.